A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

The serine protease TMPRSS2 primes SARS-CoV-2 glycoprotein for cell entry. Here, the authors perform a screen to identify drugs that reduce TMPRSS2 expression and find that halofuginone modulates proteasome-mediated degradation of TMPRSS2 and reduces entry of SARS-CoV-2.

Bibliographic Details
Main Authors: Yanwen Chen, Travis B. Lear, John W. Evankovich, Mads B. Larsen, Bo Lin, Irene Alfaras, Jason R. Kennerdell, Laura Salminen, Daniel P. Camarco, Karina C. Lockwood, Ferhan Tuncer, Jie Liu, Michael M. Myerburg, John F. McDyer, Yuan Liu, Toren Finkel, Bill B. Chen
Format: Article
Language:English
Published: Nature Portfolio 2021-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-24156-y

Internet

https://doi.org/10.1038/s41467-021-24156-y

Similar Items